San Diego, CA -- (SBWIRE) -- 08/19/2014 -- An investigation on behalf of current long-term investors in shares of Provectus Pharmaceuticals Inc (NYSEMKT:PVCT) concerning potential breaches of fiduciary duties by certain directors and officers of Provectus Pharmaceuticals was announced.

Investors who are current long term investors in Provectus Pharmaceuticals Inc (NYSEMKT:PVCT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in Provectus Pharmaceuticals Inc (NYSEMKT:PVCT) stocks follows a lawsuit filed against Provectus Pharmaceuticals Inc over alleged securities laws violations. The investigation on behalf of current long term investors in NYSEMKT:PVCT stocks, concerns whether certain Provectus Pharmaceuticals officers and directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Middle District of Tennessee the plaintiff alleges that Provectus Pharmaceuticals Inc (violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The plaintiff claims that between December 17, 2013 and May 22, 2014 defendants allegedly violated the federal securities laws by disseminating false and misleading statements to the investing public regarding the prospects for PV-10 and that as a result of defendants’ statements, Provectus Pharmaceuticals Inc (NYSEMKT:PVCT) stock traded at artificially inflated prices between December 17, 2013 and May 22, 2014, reaching a high of $5.22 per share on January 22, 2014.

On January 23, 2014, an article was published alleging that Provectus Pharmaceuticals Inc management had misled investors about the prospects for PV-10, questioning why Provectus had not yet started its promised Phase 3 randomized controlled trial of PV-10 and speculating that PV-10 may be obsolete in light of new skin cancer drugs being developed. Then on May 21, 2014, an article was published that alleged that Provectus Pharmaceuticals failed to commence a promised Phase 3 randomized controlled trial of PV-10 suitable for a Special Protocol Assessment after completing its Phase 2 study in 2010. Shares of Provectus Pharmaceuticals Inc (NYSEMKT:PVCT) declined from $3.40 per share on May 15, 2014 to $0.33 per share on May 27, 2014.

On August 15, 2014, NYSEMKT:PVCT shares closed at $0.84 per share.

Those who purchased shares of Provectus Pharmaceuticals Inc (NYSEMKT:PVCT) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com